SEC Form 3

FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Baker Bros. Advisors (GP) LLC			. Date of Event equiring Staten Month/Day/Year 7/01/2013	nent	3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ ACAD ]						
(Last) 667 MADISIC (Street) NEW YORK		(Middle) 21ST FLOOR US 10065				tionship of Reporting F all applicable) Director Officer (give title below)	Persor	n(s) to Issue 10% Owne Other (spe below)	er (Mc cify 6. li App	nth/Day/Year) ndividual or Joint licable Line) & Form filed b	ate of Original Filed //Group Filing (Check y One Reporting Person y More than One erson
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)					4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Table II - Derivative Securities Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		<ul> <li>3. Title and Amount of Secur</li> <li>Underlying Derivative Securi</li> </ul>				4. Conversion or Exercise	cise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Exercisable	Expiration Date	Title			Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	

Explanation of Responses:

## **Remarks:**

Remarks: On July 1, 2013, a Certificate of Conversion was filed with the State of Delaware to convert Baker Bros. Advisors, LLC from a limited liability company into a limited partnership named Baker Bros. Advisors LP (the "Adviser"), with Baker Bros. Advisors (GP) LLC (the "Adviser GP") as the Adviser's sole general partner. As the Adviser previously reported on its Form 4 filed on June 11, 2013, the Adviser and, collectively, therefore, its general partner have voting and dispositive power over securities held by its clients Baker Brothers Life Sciences, L.P., 14159, L.P., and 667, L.P. (the "Funds"), but neither the Adviser nor the Adviser GP have a pecuniary interest in such securities, as the Adviser may only receive a portion of the asset-based management fee. Julian C. Baker and Felix J. Baker each may be deemed to control the Adviser GP. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Baker Bros. Advisors (GP) LLC is deemed a director by deputization by virtue of its representation on the Board of Directors of ACADIA Pharmaceuticals, Inc.

No securities are beneficially owned.

## BAKER BROS. ADVISORS

(GP), LLC Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

07/11/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.